Study of Y-90, capecitabine, and atezolizumab for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of targeted radiation (Y-90), chemotherapy (capecitabine), and immunotherapy (atezolizumab) for people with colorectal cancer that has spread mainly to the liver and is no longer responding to at least two prior treatments. The goal is to see if this combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread mainly to the liver and cannot be removed with surgery.
- You have tried at least two different treatments for your cancer, and it has continued to grow.
- You are in reasonably good health (able to care for yourself and up and about more than half of your waking hours).
- You are age 18 or older.
- You have not had Y-90 radiation or radiation to the liver before.
- Your liver is not more than half filled with tumors (doctor will check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether combining Y-90 liver radiation with an immunotherapy drug (durvalumab) and chemo (gemcitabine and cisplatin) can better control locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help shrink tumors and slow disease growth, depending on how well the treatment works for your cancer type and overall health.
This trial tests a treatment called radioembolization (yttrium-90) given before surgery for colorectal cancer that has spread to the liver. It aims to shrink the liver tumors so that surgery becomes safer and more effective, and it also looks at immune markers and dosimetry to personalize the treatment.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
This trial tests a new combination of treatments for colorectal cancer that has spread to the liver. It combines a special type of radiation therapy (called PULSAR) with immunotherapy and chemotherapy plus a drug that targets blood vessels, to see if it helps shrink tumors and improve outcomes.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
Hear when a new Colorectal Carcinoma Metastatic in the Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.